AstraZeneca plc Company Profile (LON:AZN)

About AstraZeneca plc (LON:AZN)

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience. In CVMD, it is expanding its portfolio into the cardiovascular-renal area with late-stage assets, such as ZS-9 and roxadustat, as well as investing to explore the benefits of its SGLT2 and GLP-1 franchises in chronic kidney disease (CKD) and heart failure (HF). The Company has approximately 40 projects in Phase I, including 29 new molecular entities (NMEs), and 11 oncology combination projects. It has approximately 40 projects in Phase II, including 25 NMEs; four significant additional indications for projects that have reached phase II, and seven oncology combination projects.

Industry, Sector and Symbol:

Sector: N/A
Industry: N/A
Sub-Industry: N/A
Symbol: LON:AZN
CUSIP: N/A
Web: N/A

Capitalization:

Market Cap: £64.95 billion
Outstanding Shares: 1,266,000,000

Average Prices:

50 Day Moving Avg: GBX 4,804.10
200 Day Moving Avg: GBX 4,565.16
52 Week Range: GBX 3,680 - GBX 5,505

P/E:

Trailing P/E Ratio: 19.21
P/E Growth: 3.14

Sales & Book Value:

Annual Revenue: £22.29 billion
Price / Sales: 2.91
Book Value: GBX 10.26 per share
Price / Book: 5.00

Dividend:

Dividend Yield: 4.2%

Profitability:

EBIDTA: £5.84 billion

Misc:

Average Volume: 2.36 million shs.

Frequently Asked Questions for AstraZeneca plc (LON:AZN)

What is AstraZeneca plc's stock symbol?

AstraZeneca plc trades on the London Stock Exchange (LON) under the ticker symbol "AZN."

How often does AstraZeneca plc pay dividends? What is the dividend yield for AstraZeneca plc?

AstraZeneca plc announced a dividend on Thursday, February 2nd. Stockholders of record on Thursday, February 16th will be paid a dividend of GBX 150.20 per share on Monday, March 20th. This represents a dividend yield of 3.52%. The ex-dividend date of this dividend is Thursday, February 16th. This is a boost from AstraZeneca plc's previous dividend of $68.70. The official announcement can be accessed at this link. View AstraZeneca plc's Dividend History.

When will AstraZeneca plc make its next earnings announcement?

AstraZeneca plc is scheduled to release their next quarterly earnings announcement on Wednesday, July, 26th 2017. View Earnings Estimates for AstraZeneca plc.

Where is AstraZeneca plc's stock going? Where will AstraZeneca plc's stock price be in 2017?

21 equities research analysts have issued 1-year price targets for AstraZeneca plc's shares. Their forecasts range from GBX 3,650 to GBX 6,500. On average, they expect AstraZeneca plc's stock price to reach GBX 5,021.80 in the next year. View Analyst Ratings for AstraZeneca plc.

Who are some of AstraZeneca plc's key competitors?

Some companies that are related to AstraZeneca plc include Unilever plc (ULVR), British American Tobacco plc (BATS), BP plc (BP), GlaxoSmithKline plc (GSK), BHP Billiton plc (BLT), Vodafone Group plc (VOD), Diageo plc (DGE), Rio Tinto plc (RIO), Lloyds Banking Group PLC (LLOY), Barclays PLC (BARC), Reckitt Benckiser Group Plc (RB), Prudential plc (PRU), Shire PLC (SHP), Glencore PLC (GLEN), National Grid plc (NG), Redt Energy PLC (CCE), Imperial Brands PLC (IMB) and Carnival plc (CCL).

How do I buy AstraZeneca plc stock?

Shares of AstraZeneca plc and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

How much does a share of AstraZeneca plc stock cost?

One share of AstraZeneca plc stock can currently be purchased for approximately GBX 5,130.

Consensus Ratings for AstraZeneca plc (LON:AZN) (?)

Ratings Breakdown:	5 Sell Ratings, 7 Hold Ratings, 9 Buy Ratings
Consensus Rating:	Hold (Score: 2.19)
Consensus Price Target:	GBX 5,021.80

Analysts' Ratings History for AstraZeneca plc (LON:AZN)

Show:

Date	Firm	Action	Rating	Price Target
5/23/2017	JPMorgan Chase & Co.	Reiterated Rating	Neutral	GBX 4,500
5/23/2017	Liberum Capital	Reiterated Rating	Buy	GBX 5,500
5/23/2017	Shore Capital	Reiterated Rating	Hold
5/22/2017	Deutsche Bank AG	Reiterated Rating	Buy
5/20/2017	Goldman Sachs Group Inc	Set Price Target	Sell	GBX 3,900
5/20/2017	Jefferies Group LLC	Set Price Target	Neutral	GBX 4,700
5/17/2017	Berenberg Bank	Boost Price Target	Buy	GBX 5,670 -> GBX 5,850
5/15/2017	HSBC Holdings plc	Reiterated Rating	Reduce	GBX 4,200
5/11/2017	Barclays PLC	Reiterated Rating	Overweight	GBX 6,000
4/28/2017	Sanford C. Bernstein	Set Price Target	Neutral	GBX 4,736
4/27/2017	S&P Global	Set Price Target	Sell	GBX 4,500
4/27/2017	Investec	Reiterated Rating	Hold	GBX 4,600
4/24/2017	Morgan Stanley	Reiterated Rating	Buy
4/21/2017	Kepler Capital Markets	Reiterated Rating	Buy	GBX 5,000
4/19/2017	Credit Suisse Group AG	Reiterated Rating	Underperform	GBX 4,000
4/3/2017	BNP Paribas	Reiterated Rating	Neutral	GBX 5,300
4/3/2017	Beaufort Securities	Reiterated Rating	Hold
3/23/2017	Societe Generale	Reiterated Rating	Buy
2/28/2017	Bryan, Garnier & Co	Reiterated Rating	Buy	GBX 5,400
11/7/2016	Citigroup Inc	Reiterated Rating	Buy
6/24/2016	Independent Research GmbH	Set Price Target	Sell	GBX 3,650
5/10/2016	Oddo Securities	Reiterated Rating	Buy	GBX 5,400
5/5/2016	Charles Stanley	Upgrade	Strong-Buy
3/24/2016	Natixis	Reiterated Rating	Neutral	GBX 4,456
3/23/2016	Nomura	Lower Price Target	Hold	GBX 4,880 -> GBX 4,350
2/12/2016	Baader Bank	Reiterated Rating	Hold	GBX 4,400
2/9/2016	AlphaValue	Upgrade	Buy	GBX 4,640
2/4/2016	S&P Equity Research	Set Price Target	Neutral	GBX 4,500
2/2/2016	Handelsbanken	Reiterated Rating	Accumulate	GBX 5,220.30
1/28/2016	Pareto Securities	Reiterated Rating	Sell	GBX 3,855.35
1/27/2016	Swedbank	Reiterated Rating	Buy	GBX 5,115.47
1/13/2016	Nordea Equity Research	Reiterated Rating	Hold	GBX 4,698.35
7/14/2015	Danske	Upgrade	Hold	GBX 4,400

(Data available from 5/23/2015 forward)

Earnings History for AstraZeneca plc (LON:AZN)
No earnings announcements for this company have been tracked by MarketBeat.com

Earnings Estimates for AstraZeneca plc (LON:AZN)

Current Year EPS Consensus Estimate: $3.73 EPS

Dividend History by Quarter for AstraZeneca plc (LON:AZN)

Announced	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
2/2/2017	GBX 150.20	3.52%	2/16/2017	2/16/2017	3/20/2017
7/28/2016	GBX 68.70	1.37%	8/11/2016	8/11/2016	9/12/2016
2/4/2016	GBX 131	3.16%	2/18/2016	2/18/2016	3/21/2016
7/30/2015	GBX 57.50	1.33%	8/13/2015	8/13/2015	9/14/2015

(Data available from 1/1/2013 forward)

Insider Trading and Institutional Ownership History for AstraZeneca plc (LON:AZN)

Insider Trades by Quarter for AstraZeneca plc (LON:AZN)

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction
10/27/2015	Courtois,Jean-Philippe	Insider	Buy	900	GBX 4,423	£39,807
8/28/2015	Soriot,Pascal	Insider	Buy	76,300	GBX 3,960	£3,021,480
5/7/2015	Marc Dunoyer	Insider	Buy	10,000	GBX 4,397	£439,700
4/30/2015	Ann Cairns	Insider	Buy	1,100	GBX 4,455	£49,005
4/29/2015	Shriti Vadera	Insider	Buy	3,500	GBX 4,563	£159,705
4/28/2015	Graham Chipchase	Insider	Buy	1,100	GBX 4,606	£50,666
4/27/2015	Bruce Burlington	Insider	Buy	600	GBX 4,662	£27,972

(Data available from 1/1/2013 forward)

Headline Trends for AstraZeneca plc (LON:AZN) Latest Headlines for AstraZeneca plc (LON:AZN)

Source:

Date	Headline
	Deutsche Bank AG Reiterates "Buy" Rating for AstraZeneca plc (AZN) www.americanbankingnews.com - May 22 at 7:00 PM
	[$$] AstraZeneca sells Seloken European rights for $300m finance.yahoo.com - May 22 at 3:46 PM
	Severe asthma drug shows AstraZeneca promise beyond cancer finance.yahoo.com - May 22 at 3:46 PM
	AstraZeneca, Recordati Enter Deal For Seloken; AstraZeneca To Receive $300 Mln www.nasdaq.com - May 22 at 10:20 AM
	AstraZeneca plc (AZN) Given a GBX 4,700 Price Target at Jefferies Group LLC www.americanbankingnews.com - May 21 at 4:20 PM
	AstraZeneca plc (AZN) Given a GBX 3,900 Price Target by Goldman Sachs Group Inc Analysts www.americanbankingnews.com - May 21 at 10:34 AM
	[$$] Biotech Investor Clarus Ventures Raising $880 Million Fund finance.yahoo.com - May 19 at 9:19 AM
	Berenberg Bank Increases AstraZeneca plc (AZN) Price Target to GBX 5,850 www.americanbankingnews.com - May 19 at 12:08 AM
	AstraZeneca PLC 'one for the brave', but still a 'buy', according to leading City broker www.msn.com - May 17 at 12:07 PM
	AstraZeneca Plc – Value Analysis (LONDON:AZN) : May 16, 2017 finance.yahoo.com - May 16 at 3:52 PM
	AstraZeneca plc (AZN) Upgraded at Shore Capital www.americanbankingnews.com - May 16 at 12:20 PM
	JPMorgan Chase & Co. Reiterates Neutral Rating for AstraZeneca plc (AZN) www.americanbankingnews.com - May 14 at 12:08 PM
	Jefferies Group LLC Lowers AstraZeneca plc (AZN) Price Target to GBX 4,700 www.americanbankingnews.com - May 13 at 2:05 PM
	AstraZeneca, MedImmune Report Positive Results For Imfinzi Trial In NSCLC www.nasdaq.com - May 12 at 9:20 PM
	AstraZeneca Group plc (AZN) seekingalpha.com - May 12 at 4:20 PM
	AstraZeneca Shows That With Immune Cancer Drugs, No One Knows What's Next finance.yahoo.com - May 12 at 4:20 PM
	FTSE 100 closes at an all-time high as AstraZeneca rallies, pound stalls finance.yahoo.com - May 12 at 4:20 PM
	Is AstraZeneca The Next Big Player In Cancer Immunotherapies? finance.yahoo.com - May 12 at 4:20 PM
	AstraZeneca Shares Jump On Cancer Trial That Rivals Dow's Merck finance.yahoo.com - May 12 at 4:20 PM
	AstraZeneca's tralokinumab flunks late-stage asthma study - Seeking Alpha seekingalpha.com - May 10 at 11:57 PM
	Shore Capital Reiterates "Sell" Rating for AstraZeneca plc (AZN) www.americanbankingnews.com - May 10 at 12:33 PM
	AstraZeneca's New Drug: Too Little, Too Late? - Seeking Alpha seekingalpha.com - May 8 at 10:42 AM
	Pharma Stock Roundup: Merck, Pfizer Report Q1 Earnings, J&J Talc Powder Lawsuit finance.yahoo.com - May 8 at 10:42 AM
	AstraZeneca plc's (AZN) "Overweight" Rating Reaffirmed at Barclays PLC www.americanbankingnews.com - May 7 at 8:55 PM
	AstraZeneca plc (AZN) Rating Reiterated by Shore Capital www.americanbankingnews.com - May 7 at 4:02 PM
	AstraZeneca plc (AZN) Earns "Reduce" Rating from HSBC Holdings plc www.americanbankingnews.com - May 6 at 10:34 PM
	AstraZeneca plc (AZN) Given Consensus Recommendation of "Hold" by Analysts www.americanbankingnews.com - May 3 at 10:06 AM
	AstraZeneca plc (AZN) Given Hold Rating at Jefferies Group LLC www.americanbankingnews.com - April 30 at 7:58 PM
	AstraZeneca plc's (AZN) "Buy" Rating Reiterated at Liberum Capital www.americanbankingnews.com - April 30 at 6:54 PM
	[$$] Pearson defends CEO pay ahead of investor showdown finance.yahoo.com - April 30 at 5:04 PM
	AstraZeneca plc (AZN) Stock Rating Reaffirmed by Shore Capital www.americanbankingnews.com - April 30 at 3:47 PM
	AstraZeneca plc (AZN) Stock Rating Reaffirmed by Investec www.americanbankingnews.com - April 30 at 11:28 AM
	AstraZeneca plc (AZN) Given New GBX 5,350 Price Target at Deutsche Bank AG www.americanbankingnews.com - April 30 at 9:56 AM
	AstraZeneca plc (AZN) Rating Reiterated by Barclays PLC www.americanbankingnews.com - April 30 at 9:23 AM
	AstraZeneca plc (AZN) Price Target Cut to GBX 4,200 by Analysts at HSBC Holdings plc www.americanbankingnews.com - April 30 at 9:22 AM
	JPMorgan Chase & Co. Increases AstraZeneca plc (AZN) Price Target to GBX 4,500 www.americanbankingnews.com - April 30 at 6:22 AM
	AstraZeneca plc (AZN) Given a GBX 4,500 Price Target at S&P Global www.americanbankingnews.com - April 28 at 8:56 PM
	AstraZeneca plc (AZN) Given a GBX 5,670 Price Target at Berenberg Bank www.americanbankingnews.com - April 28 at 8:56 PM
	AstraZeneca plc's (AZN) Hold Rating Reaffirmed at Investec www.americanbankingnews.com - April 28 at 8:54 PM
	AstraZeneca plc (AZN) Given "Sell" Rating at Shore Capital www.americanbankingnews.com - April 28 at 8:54 PM
	AstraZeneca plc (AZN) Given Buy Rating at Liberum Capital www.americanbankingnews.com - April 28 at 7:12 PM
	AstraZeneca plc's (AZN) "Hold" Rating Reaffirmed at Jefferies Group LLC www.americanbankingnews.com - April 28 at 7:04 PM
	Edited Transcript of AZN.L earnings conference call or presentation 27-Apr-17 11:00am GMT finance.yahoo.com - April 28 at 4:44 PM
	AstraZeneca (AZN) Q1 Earnings Beat, Revenues Meet Estimates finance.yahoo.com - April 28 at 4:44 PM
	[$$] Biotech and big pharma reap rewards from partnerships finance.yahoo.com - April 28 at 4:44 PM
	Sanford C. Bernstein Analysts Give AstraZeneca plc (AZN) a GBX 4,736 Price Target www.americanbankingnews.com - April 28 at 6:38 AM
	AstraZeneca Plc's (AZN) CEO Pascal Soriot on Q1 2017 Results - Earnings Call Transcript - Seeking Alpha seekingalpha.com - April 27 at 9:14 PM
	AstraZeneca plc (AZN) PT Set at GBX 4,500 by S&P Global www.americanbankingnews.com - April 27 at 3:48 PM
	AstraZeneca plc (AZN) Given a GBX 5,670 Price Target by Berenberg Bank Analysts www.americanbankingnews.com - April 27 at 11:26 AM
	What Analysts Recommend for AstraZeneca finance.yahoo.com - April 26 at 4:07 PM